Jeff Baxter
Chief Executive Officer bei VBI VACCINES INC.
Vermögen: 12 225 $ am 31.03.2024
Profil
Jeffrey R. Baxter ist President, Chief Executive Officer & Director bei VBI Vaccines, Inc. und ein unabhängiger Non-Executive Director bei Chromadex Corp. sowie President, Chief Executive Officer & Director bei VBI Vaccines (Delaware), Inc. und President, Chief Executive Officer & Director bei Variation Biotechnologies (US), Inc. Er ist Mitglied des Board of Directors bei VBI Vaccines, Inc. und Chromadex Corp. sowie bei VBI Vaccines (Delaware), Inc. und Variation Biotechnologies (US), Inc. Herr Baxter war zuvor als SVP-Finance, Operations, Research & Development bei GlaxoSmithKline Plc, als Principal bei British American Tobacco plc, als Managing Partner bei The Column Group LLC und als Principal bei Unilever Plc tätig. Er erhielt seinen Bachelor-Abschluss von der Thames Valley University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
VBI VACCINES, INC.
0,09% | 27.07.2023 | 20 274 ( 0,09% ) | 12 225 $ | 31.03.2024 |
Aktive Positionen von Jeff Baxter
Unternehmen | Position | Beginn |
---|---|---|
VBI VACCINES INC. | Chief Executive Officer | 01.05.2016 |
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Chief Executive Officer | 22.09.2009 |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Chief Executive Officer | 01.07.2014 |
Ehemalige bekannte Positionen von Jeff Baxter
Unternehmen | Position | Ende |
---|---|---|
CHROMADEX CORPORATION | Director/Board Member | 04.04.2022 |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Chief Investment Officer | 28.02.2009 |
GSK PLC | Corporate Officer/Principal | 01.07.2006 |
UNILEVER PLC | Corporate Officer/Principal | - |
BRITISH AMERICAN TOBACCO P.L.C. | Corporate Officer/Principal | - |
Ausbildung von Jeff Baxter
University of West London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
BRITISH AMERICAN TOBACCO P.L.C. | Consumer Non-Durables |
UNILEVER PLC | Consumer Non-Durables |
GSK PLC | Health Technology |
CHROMADEX CORPORATION | Health Technology |
VBI VACCINES INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Health Technology |